Product Code: ETC069958 | Publication Date: Jul 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
Biosimilars are biological products that are highly similar to approved reference biologic drugs in terms of safety, efficacy, and quality. They offer a more affordable alternative to expensive biologic medications and contribute to cost savings in healthcare systems.
Biosimilars are often priced lower than their reference biologics, leading to cost savings for patients, healthcare providers, and the government. The prevalence of chronic diseases in Saudi Arabia, such as diabetes, cancer, and autoimmune disorders, drives the demand for affordable treatment options like biosimilars. The Saudi Arabia government`s initiatives to promote biosimilar adoption and encourage domestic production contribute to market growth.
Obtaining regulatory approval for biosimilars can be a complex and time-consuming process, which may pose challenges for manufacturers. Building trust and acceptance among physicians and patients regarding the efficacy and safety of biosimilars is crucial for market growth.
The Covid-19 pandemic may have had varying impacts on the Saudi Arabia Biosimilars market. During the pandemic, disruptions in healthcare services and supply chains could have affected biosimilar availability and access. However, the pandemic`s focus on healthcare cost optimization and affordable treatment options may have accelerated interest in biosimilars.
Some well-known companies involved in biosimilars production that have a presence in Saudi Arabia include, Sandoz International GmbH (a division of Novartis), Pfizer Inc., Amgen Inc., and Celltrion Inc.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Saudi Arabia Biosimilars Market Overview |
3.1 Saudi Arabia Country Macro Economic Indicators |
3.2 Saudi Arabia Biosimilars Market Revenues & Volume, 2020 & 2027F |
3.3 Saudi Arabia Biosimilars Market - Industry Life Cycle |
3.4 Saudi Arabia Biosimilars Market - Porter's Five Forces |
3.5 Saudi Arabia Biosimilars Market Revenues & Volume Share, By Product, 2020 & 2027F |
3.6 Saudi Arabia Biosimilars Market Revenues & Volume Share, By Indication, 2020 & 2027F |
3.7 Saudi Arabia Biosimilars Market Revenues & Volume Share, By Manufacturing, 2020 & 2027F |
4 Saudi Arabia Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Saudi Arabia Biosimilars Market Trends |
6 Saudi Arabia Biosimilars Market, By Types |
6.1 Saudi Arabia Biosimilars Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 Saudi Arabia Biosimilars Market Revenues & Volume, By Product, 2018 - 2027F |
6.1.3 Saudi Arabia Biosimilars Market Revenues & Volume, By Insulin, 2018 - 2027F |
6.1.4 Saudi Arabia Biosimilars Market Revenues & Volume, By Follitropin, 2018 - 2027F |
6.1.5 Saudi Arabia Biosimilars Market Revenues & Volume, By Calcitonin, 2018 - 2027F |
6.1.6 Saudi Arabia Biosimilars Market Revenues & Volume, By Glucagon, 2018 - 2027F |
6.1.7 Saudi Arabia Biosimilars Market Revenues & Volume, By Teriparatide, 2018 - 2027F |
6.1.8 Saudi Arabia Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.2 Saudi Arabia Biosimilars Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Saudi Arabia Biosimilars Market Revenues & Volume, By Oncology, 2018 - 2027F |
6.2.3 Saudi Arabia Biosimilars Market Revenues & Volume, By Offsite Treatment, 2018 - 2027F |
6.2.4 Saudi Arabia Biosimilars Market Revenues & Volume, By Chronic Disorders, 2018 - 2027F |
6.2.5 Saudi Arabia Biosimilars Market Revenues & Volume, By Blood Disorders, 2018 - 2027F |
6.2.6 Saudi Arabia Biosimilars Market Revenues & Volume, By Infectious Diseases, 2018 - 2027F |
6.2.7 Saudi Arabia Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.3 Saudi Arabia Biosimilars Market, By Manufacturing |
6.3.1 Overview and Analysis |
6.3.2 Saudi Arabia Biosimilars Market Revenues & Volume, By Outsourced, 2018 - 2027F |
6.3.3 Saudi Arabia Biosimilars Market Revenues & Volume, By In-house, 2018 - 2027F |
7 Saudi Arabia Biosimilars Market Import-Export Trade Statistics |
7.1 Saudi Arabia Biosimilars Market Export to Major Countries |
7.2 Saudi Arabia Biosimilars Market Imports from Major Countries |
8 Saudi Arabia Biosimilars Market Key Performance Indicators |
9 Saudi Arabia Biosimilars Market - Opportunity Assessment |
9.1 Saudi Arabia Biosimilars Market Opportunity Assessment, By Product, 2020 & 2027F |
9.2 Saudi Arabia Biosimilars Market Opportunity Assessment, By Indication, 2020 & 2027F |
9.3 Saudi Arabia Biosimilars Market Opportunity Assessment, By Manufacturing, 2020 & 2027F |
10 Saudi Arabia Biosimilars Market - Competitive Landscape |
10.1 Saudi Arabia Biosimilars Market Revenue Share, By Companies, 2020 |
10.2 Saudi Arabia Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |